I am a hacker in the dark of a very cold night

path :/var/www/html/vorne.webheaydemo.com

upload file:

List of files:

name file size edit permission action
carbon3333 KBMarch 05 2024 07:21:060666
carbon.bat133 KBMarch 05 2024 07:21:060666
generate-defuse-key3396 KBMarch 05 2024 07:21:140666
generate-defuse-key.bat146 KBMarch 05 2024 07:21:140666
patch-type-declarations3438 KBMarch 05 2024 07:21:020666
patch-type-declarations.bat150 KBMarch 05 2024 07:21:020666
php-parse3351 KBMarch 19 2024 12:13:240666
php-parse.bat136 KBMarch 19 2024 12:13:240666
phpunit3692 KBMarch 05 2024 07:21:240666
phpunit.bat134 KBMarch 05 2024 07:21:240666
pint3333 KBMarch 05 2024 07:21:140666
pint.bat131 KBMarch 05 2024 07:21:140666
psysh3318 KBMarch 19 2024 12:13:240666
psysh.bat132 KBMarch 19 2024 12:13:240666
sail941 KBMarch 19 2024 12:13:240666
sail.bat152 KBMarch 19 2024 12:13:240666
var-dump-server3405 KBMarch 05 2024 07:20:560666
var-dump-server.bat142 KBMarch 05 2024 07:20:560666
yaml-lint3369 KBMarch 05 2024 07:21:140666
yaml-lint.bat136 KBMarch 05 2024 07:21:140666
VORNE.AI - Campaign Details
Company Details: 1. Name: Association for Humanitarian Development 2. Address: House # 39b Block B Unit No 2 Latifabad Hyderabad Sindh Pakistan 3. Key Person: Abdul Khurshid Bhatti (President/CEO) 4. Website: http://www.ahdpak.org/ Climate Change Mitigation: Nextsense’s mission is to reduce infections by improving infection prevention control practices using modern, safe, and eco-sustainable technologies Currrent Stage: Scale-up Stage: Optimization of operations, expansion of the customer base, and securing resources for sustainable growth and increased market reach., Growth stage: Focus on continuous scaling, market expansion, and solidification of the company's position, evolving from startup to an established player in the industry. Innovation Alignment: Biovitae addresses health challenges intensified by climate-related factors in two ways. #1 - Chemical Disinfectants (CD) and UV light have seen a multiple fold increase in use after the COVID-19 pandemic, this directly increases the toxicity in our natural environment which is detrimental to our health. Biovitae eliminates the need for the use of CD/UV, resulting a net positive effect on our environment and health. #2- Furthermore, climate change is directly linked the increase of superbugs and AMR. Biovitae is highly effective on the eradication of superbugs (ie. MRSA), creating a bio-safe environment for humans & animals. Soulution Impact on Health Equity: Biovitae is a unique technology which aligns with the One Health approach. Biovitae is a UV-free LED lighting technology that utilises a combination of multiple wavelengths in the visible light spectrum which are effective in killing bacteria, fungi, mould, spores, and also viruses on surfaces & air. Active ingredients commonly found Chemical Disinfectants (such as Quaternary ammonium compounds/QACs) are extremely toxic to the environment – spreading into water, soil and the atmosphere. UV light generates dangerous ozone gas, and have a short operational life span. Biovitae is an environmentally friendly alternative to dangerous conventional sanitisation methods such as Chemical Disinfection/UV. Impact Potential: a) Biovitae is exactly tailored for the use in LMIC and low-resource settings. In LMICs Healthcare facilities are often not purpose-built and are usually converted buildings from other types of facilities, lack access to chemical disinfectants, water, energy or trained personnel. Biovitae offers a real solution for these low-resource settings as it is compatible with all material types, does not require any training to use or install and does not require any chemicals or water. In addition, Biovitae is highly energy efficient, allowing for power over solar panels or batteries. Biovitae can be easily locally assembled, allowing for LMICs to develop internal capacities and knowhow. b) Biovitae has been validated over 30x in 6 different countries by independent laboratories. To name a few examples, Bioviate is highly effective to eradiacate superbugs such as MRSA, S. aureus, P. aeruginosa, and E.Coli. Bioviate has also been tested on viruses with over a 99% reduction of SARS-CoV-2, Monkeypox, and Yellow Fever Virus (YFV). Biovitae has been installed in a number of hospitals such as the Emergency hospital of Rome Fiumicino Airport and Montevergine Hospital in Campania, where the number of Hospital Acquired Infections (HAIs) has decreased thanks to the effective and continuous sanitisation Business Viability and Sustainability: Biovitae's Total Addressable Market is essentially anywhere where there is indoor lighting infrastructure where there is potential infection risk, and as such we can base our TAM on a combination of the General Lighting Market and the UV sanitisation market. The LED lighting market was valued at USD 50.9 billion (6.97% CAGR 2022-2027), and the UV sanitisation market was valued at USD 620 million (17.8% CAGR 20212026). The growing consumer awareness about the importance of the importance of microbiologically safe environments, government mandates for energy efficiency and cleantech are the drivers for the growing adoption of LED sanitisation technology. Biovitae will transform the lighting market. We are not simply positioning this technology as a sanitisation solution, but as the future of lighting. The escalating challenge of Antimicrobial Resistance (AMR) and the European Union's decisive mandates to address this issue serve as significant market drivers for light sanitization technologies like Biovitae. As the EU intensifies its efforts to combat AMR through initiatives such as the One Health approach, which emphasizes reducing antibiotic consumption and combating AMR, there is an increasing demand for innovative, non-pharmaceutical solutions. This shift presents a substantial market opportunity for light sanitisation technologies, which offer an effective, chemical-free alternative to traditional methods. We have already closed over 30 installations in 4 countries, and plan many more for 2024.

Location: Africa

Deadline: 2024-05-31